TherapeuticsMD (TXMD) EV to EBIT (2011 - 2026)

TherapeuticsMD (TXMD) has reported EV to EBIT for 16 consecutive years, with 20.09 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBIT fell 89.74% year-over-year to 20.09; the trailing twelve-month figure through Jun 2026 stood at 4.15 (down 112.02% YoY), and the FY2025 full-year result was 2.59, down 226.18% from the prior year.
• EV to EBIT rose to 20.09 in Q2 2026 per TXMD's latest filing, from 20.69 in the prior quarter.
• Across five years, EV to EBIT topped out at 0.15 in Q4 2022 and bottomed at 20.69 in Q1 2026.
• Historically, EV to EBIT has averaged 9.37 across 5 years, with a median of 7.48 in 2022.
• The sharpest annual moves came in 2022 and 2023: EV to EBIT soared 99.93% in 2022, then tumbled 8599.15% in 2023.
• Over 5 years, EV to EBIT stood at 0.15 in 2022, then tumbled by 8599.15% to 13.42 in 2023, then jumped by 44.47% to 7.45 in 2024, then gained by 1.58% to 7.33 in 2025, then sank by 173.86% to 20.09 in 2026.
• According to Business Quant data, EV to EBIT over the past three periods registered 20.09, 20.69, and 7.33 for Q2 2026, Q1 2026, and Q4 2025 respectively.